Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. Vet Comp Oncol. 2012;10:163-73.BAVCAR S,ARGYLE D J. Receptor tyrosine kinase inhibitors:molecularly targeted drugs for veterinary cancer therapy[J].VETERINARY AND COMPARATIVE ONCOLOGY,2012,(03):163-173....
Proteinuria and hypertension with tyrosine kinase inhibitors Praveen Kandula, Rajiv Agarwal, in Kidney International, 2011 TYROSINE KINASE Tyrosine kinases belong to the family of protein kinases and are classified in two broad categories: receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases....
FULL PAPER British Journal of Cancer (2017) 116, 1366–1373 | doi: 10.1038/bjc.2017.88 Keywords: heart failure; tyrosine kinase-targeting drugs; cardio-oncology; adverse effects Tyrosine kinase-targeting drugs-associated heart failure N Gronich*,1, I Lavi1, O Barnett-Griness1, W Saliba1, D...
Thus, inhibitors that block the activity of tyrosine kinases and their subsequent signaling pathways play a key role in the development of therapeutic strategies for cancer and the other enzyme-related pathologies. Generally, there are two classes of protein tyrosine kinase inhibitors. One type binds...
Bruton's tyrosine kinase (BTK) is a non-receptor protein kinase that plays a crucial role in various biological processes, including immune system function and cancer development. Therefore, inhibition of BTK has been proposed as a therapeutic strategy f
Alk Inhibitors Alk Inhibitors fall under the category of tyrosine kinase inhibitors Search Run-off in the Tire-Wear Ingredient, Hexamethoxymethyl-Melamine straight into Downtown Watersheds. Posted onDecember 30, 2024 Reply In most 94 eyes, a number of associated with the 6 areas associated with ...
cells is severely impaired [7,8,9,10]. Importantly, BTK has received large interest since small-molecule inhibitors of this kinase have shown excellent anti-tumor activity in clinical studies [11,12]. In particular, the orally administered BTK inhibitor ibrutinib, which forms a covalent bond ...
Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JBA phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with ...
Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelogenous leukemia...
To test this hypothesis, we utilized two tyrosine kinase inhibitors, lestaurtinib (CEP-701) and crizotinib, that were previously reported as efficient blockers of NTRK1 auto- phosphorylation and downstream signaling.40,41 As expected, both drugs dramatically reduced the NGF-mediated increase in ...